AR040724A1 - Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento - Google Patents
Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamentoInfo
- Publication number
- AR040724A1 AR040724A1 AR20030102720A ARP030102720A AR040724A1 AR 040724 A1 AR040724 A1 AR 040724A1 AR 20030102720 A AR20030102720 A AR 20030102720A AR P030102720 A ARP030102720 A AR P030102720A AR 040724 A1 AR040724 A1 AR 040724A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fibrosis
- halo
- ulcers
- disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000017169 kidney disease Diseases 0.000 abstract 3
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 2
- 102000009618 Transforming Growth Factors Human genes 0.000 abstract 2
- 108010009583 Transforming Growth Factors Proteins 0.000 abstract 2
- 208000025865 Ulcer Diseases 0.000 abstract 2
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 231100000397 ulcer Toxicity 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 102000018918 Activin Receptors Human genes 0.000 abstract 1
- 108010052946 Activin Receptors Proteins 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010056340 Diabetic ulcer Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000018565 Hemochromatosis Diseases 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 abstract 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 abstract 1
- 208000002260 Keloid Diseases 0.000 abstract 1
- 206010023421 Kidney fibrosis Diseases 0.000 abstract 1
- 206010027398 Mesenteric fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010051246 Photodermatosis Diseases 0.000 abstract 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 abstract 1
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 abstract 1
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000004221 bone function Effects 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000000718 duodenal ulcer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 imidazopyridine compound Chemical class 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000001117 keloid Anatomy 0.000 abstract 1
- 230000007658 neurological function Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 230000008845 photoaging Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0217783.0A GB0217783D0 (en) | 2002-07-31 | 2002-07-31 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040724A1 true AR040724A1 (es) | 2005-04-20 |
Family
ID=9941484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102720A AR040724A1 (es) | 2002-07-31 | 2003-07-29 | Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050234029A1 (https=) |
| EP (1) | EP1543003B1 (https=) |
| JP (1) | JP2005537291A (https=) |
| AR (1) | AR040724A1 (https=) |
| AT (1) | ATE326467T1 (https=) |
| AU (1) | AU2003255323A1 (https=) |
| DE (1) | DE60305332T2 (https=) |
| ES (1) | ES2259419T3 (https=) |
| GB (1) | GB0217783D0 (https=) |
| TW (1) | TW200413366A (https=) |
| WO (1) | WO2004013138A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| WO2004013135A1 (en) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| UA80296C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| AU2006239929B2 (en) | 2005-04-22 | 2011-11-03 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
| US7709468B2 (en) * | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| CN101611007A (zh) | 2006-12-20 | 2009-12-23 | 先灵公司 | 新颖的jnk抑制剂 |
| US20100298314A1 (en) * | 2006-12-20 | 2010-11-25 | Schering Corporation | Novel jnk inhibitors |
| BRPI0817434A2 (pt) * | 2007-10-17 | 2015-06-16 | Novartis Ag | Composto orgânicos |
| AU2008345681A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth Llc | Imidazo [1,2-a] pyridine compounds |
| EA201001687A1 (ru) * | 2008-04-29 | 2011-06-30 | Новартис Аг | Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 ) |
| PH12012500778A1 (en) | 2009-10-30 | 2012-11-26 | Janssen Pharmaceutica Nv | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS |
| KR101552760B1 (ko) | 2009-12-18 | 2015-09-11 | 미쓰비시 타나베 파마 코퍼레이션 | 신규 항혈소판약 |
| AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
| US9073918B2 (en) | 2010-05-20 | 2015-07-07 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5 |
| US20120309796A1 (en) | 2011-06-06 | 2012-12-06 | Fariborz Firooznia | Benzocycloheptene acetic acids |
| BR112013033375B1 (pt) | 2011-06-27 | 2022-05-10 | Janssen Pharmaceutica N.V | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário |
| HK1206250A1 (en) | 2012-06-26 | 2016-01-08 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| WO2014009305A1 (en) | 2012-07-09 | 2014-01-16 | Janssen Pharmaceutica Nv | Inhibitors of phosphodiesterase 10 enzyme |
| CN108341769A (zh) * | 2018-05-13 | 2018-07-31 | 浙江凯普化工有限公司 | 多取代的6-氟皮考啉酸的制备方法 |
| CN115975224B (zh) * | 2023-03-16 | 2023-08-08 | 四川大学 | 一种pH/ROS双响应的组织粘附载药水凝胶及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11302177A (ja) * | 1998-04-27 | 1999-11-02 | Otsuka Pharmaceut Factory Inc | 腎炎治療剤 |
| GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| JP2004517068A (ja) * | 2000-11-16 | 2004-06-10 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
| GB0027987D0 (en) * | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| GB0100762D0 (en) * | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| WO2004013135A1 (en) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
-
2002
- 2002-07-31 GB GBGB0217783.0A patent/GB0217783D0/en not_active Ceased
-
2003
- 2003-07-29 EP EP03766355A patent/EP1543003B1/en not_active Expired - Lifetime
- 2003-07-29 AT AT03766355T patent/ATE326467T1/de not_active IP Right Cessation
- 2003-07-29 JP JP2004525375A patent/JP2005537291A/ja active Pending
- 2003-07-29 US US10/522,967 patent/US20050234029A1/en not_active Abandoned
- 2003-07-29 ES ES03766355T patent/ES2259419T3/es not_active Expired - Lifetime
- 2003-07-29 AR AR20030102720A patent/AR040724A1/es not_active Application Discontinuation
- 2003-07-29 DE DE60305332T patent/DE60305332T2/de not_active Expired - Fee Related
- 2003-07-29 WO PCT/EP2003/008390 patent/WO2004013138A2/en not_active Ceased
- 2003-07-29 TW TW092120589A patent/TW200413366A/zh unknown
- 2003-07-29 AU AU2003255323A patent/AU2003255323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004013138A3 (en) | 2004-03-25 |
| ATE326467T1 (de) | 2006-06-15 |
| EP1543003A2 (en) | 2005-06-22 |
| WO2004013138A2 (en) | 2004-02-12 |
| DE60305332D1 (de) | 2006-06-22 |
| EP1543003B1 (en) | 2006-05-17 |
| AU2003255323A8 (en) | 2004-02-23 |
| ES2259419T3 (es) | 2006-10-01 |
| JP2005537291A (ja) | 2005-12-08 |
| AU2003255323A1 (en) | 2004-02-23 |
| GB0217783D0 (en) | 2002-09-11 |
| DE60305332T2 (de) | 2007-04-19 |
| US20050234029A1 (en) | 2005-10-20 |
| TW200413366A (en) | 2004-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040724A1 (es) | Compuesto de imidazopiridina, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
| RU2441869C2 (ru) | Противовирусные соединения | |
| AR040726A1 (es) | Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
| AR040595A1 (es) | Derivados de amina sustituida y metodos de uso | |
| CA2668997A1 (en) | 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors | |
| JP2018535963A5 (https=) | ||
| AR029717A1 (es) | Derivados del pro-farmaco de 4-fenil-piridina | |
| CY1105035T1 (el) | Συγχωνευμενα με αρυλιο ή ετεροαρυλιο παραγωγα της ιμιδαζολης ως αντιφλεγμονωδεις και αναλγητικοι παραγοντες | |
| RU2013151803A (ru) | Бициклические гетероциклические соединения и их применения в терапии | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| ZA200603474B (en) | Alkoxy substituted imidazoquinolines | |
| CA2628131A1 (en) | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods | |
| CR20200418A (es) | Inhibidores de orginasa y sus mètodos de uso antecedentes | |
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| RU2008142600A (ru) | Органическое соединение | |
| AR068635A1 (es) | Derivados de 1, 1, 1 - trifluor - 2 - hidroxi - 3 - fenilpropano, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion del receptor de glucocorticoides. | |
| JP2012511588A5 (https=) | ||
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| MX2012002534A (es) | Derivados de (tio) morfolina como moduladores de esfingosin-1-fosfato. | |
| AR048334A1 (es) | Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta. | |
| ME02355B (me) | Derivati 2-0ks0-1-pirolidinil imidazotiadiazola | |
| JP2020511547A5 (https=) | ||
| AR062405A1 (es) | Derivados de isoindol | |
| HRP20151419T1 (hr) | Derivati 2-okso-1-imidazolidinil imidazotiadiazola |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |